Home › Funds › Summit Global Investments › VRTX

Summit Global Investments position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

Summit Global Investments reported holding 9,982 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$5.2M, representing 0.26% of its reported portfolio and ranking #47 among its reported holdings. Summit Global Investments has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)9.98K sh
Reported value held$5.22M
Portfolio Weight0.26%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Summit Global Investments's VRTX position evolved

Summit Global Investments first disclosed a stake in VRTX in Q3 2023 at 51,470 shares (US$17.9M). The position peaked in Q4 2023 at 74,588 shares, worth US$30.3M. Across 13 filings, Summit Global Investments increased the stake 5 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 9,982 shares valued at US$5.2M — an increase of 2,800 shares quarter over quarter.. Notable position changes include a 45% increase in Q4 2023 (shares rose 2% over the following quarter), a 77% trim in Q2 2024 (shares were roughly flat over the following quarter), a 84% increase in Q2 2026 (shares rose 5% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 51.47K $17.90M New
Q4 2023 74.59K $30.35M Add
Q1 2024 41.91K $17.52M Reduce
Q2 2024 9.62K $4.51M Reduce
Q3 2024 5.79K $2.69M Reduce
Q4 2024 4.98K $2.00M Reduce
Q1 2025 3.57K $1.73M Reduce
Q2 2025 3.91K $1.74M Add
Q3 2025 4.97K $1.95M Add
Q4 2025 4.20K $1.91M Reduce
Q1 2026 3.90K $1.74M Reduce
Q2 2026 7.18K $3.57M Add
Q3 2026 9.98K $5.22M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has Summit Global Investments held VRTX?

Summit Global Investments has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Summit Global Investments's current position in VRTX?

As of Q3 2026, Summit Global Investments holds 9.98K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $5.22M, representing 0.26% of its reported portfolio and ranking #47.

Has Summit Global Investments been buying or selling VRTX?

In the latest 13F filing (Q3 2026), Summit Global Investments increased its position in VRTX. The position peaked in Q4 2023 at 74.59K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.